Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, QC, May 15, 2019 /CNW Telbec/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced the voting results from its 2019 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec.

Election of Directors
The detailed results of the votes for director nominees listed in the Management Information Circular dated March 18, 2019 (the "Circular") are as follows:

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel N. Chicoine	7,456,570	587,320	92.7%	7.3%
David A. Copeland	7,465,703	578,187	92.8%	7.2%
Anthony E. Dobranowski	7,476,684	567,206	92.9%	7.1%
John C. London	7,451,239	592,651	92.6%	7.4%
Dr. Jean-François Tremblay	7,483,476	560,414	93.0%	7.0%
Thomas Schlader	7,483,400	560,490	93.0%	7.0%

Appointment of External Auditors
Ernst and Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present, or represented by proxy, and the directors were authorized to determine their remuneration. The shareholders voted as follows:

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Ernst & Young LLP appointed	7,796,409	597,104	92.9%	7.1%

Approval of Amendments to and Continuation of Crescita's Shareholder Rights Plan
The resolution to approve the amendments to and the continuation of Crescita's Shareholder Rights Plan, as described in the Circular, was approved by a majority of the votes cast by shareholders present at the meeting or by proxy, as follows:

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Shareholder Rights Plan approved	7,415,592	628,298	92.2%	7.8%

About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain.  Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin.  For additional information, please visit www.crescitatherapeutics.com.

SOURCE Crescita Therapeutics Inc.

Investor Relations, Email: [email protected]

Related Links

www.crescitatherapeutics.com